Investors

Press Releases

 
Press Releases
  Date Title View
Jun 15, 2017
JERSEY CITY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced the publication of results from a study evaluating the activity of SCY-078 against three hundred a...
Jun 13, 2017
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer, will participate in a panel at the ...
Jun 5, 2017
Potent and broad activity of SCY-078 shown against more than 300 clinical Candida isolates    Multiple studies confirm high compatibility of SCY-078 with other antifungals and favorable safety profile  JERSEY CITY, N.J., June 05, 2017 (GLOBE...
May 24, 2017
JERSEY CITY, N.J., May 24, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies ...
May 11, 2017
SCY-078 may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC Multiple studies confirm SCY-078's broad spectrum of activity against Candida species, including resistant strains JERSEY CITY, N.J., May 11, 2017 (G...
May 8, 2017
JERSEY CITY, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult...
Apr 25, 2017
Presentations support SCY-078's potential as a novel treatment for Candida infections including multidrug-resistant strains Favorable safety profile of SCY-078 supported by clinical studies presented Conference call to review ECCMID SCY-078 d...
Apr 21, 2017
JERSEY CITY, N.J., April 21, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficu...
Apr 12, 2017
Oral presentation of Phase 2 study discusses oral SCY-078 in patients with invasive candidiasis Potent in vitro activity of SCY-078 against multidrug-resistant fungal pathogen Candida auris In vitro synergy of SCY-078 in combination with other antifungals ...
Mar 29, 2017
JERSEY CITY, N.J., March 29, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present at the 16th Annual Needham Healthcare Conference at...
1
... NextLast
= add release to Briefcase